 Immunotherapy, Adoptive
"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
| Descriptor ID |
D016219
|
| MeSH Number(s) |
E02.095.465.425.400.330.050.400 E05.478.550.520.050.400
|
| Concept/Terms |
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in this website by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 3 | 1 | 4 | | 1994 | 0 | 1 | 1 | | 1995 | 0 | 1 | 1 | | 1997 | 2 | 0 | 2 | | 1998 | 1 | 0 | 1 | | 2001 | 1 | 1 | 2 | | 2002 | 1 | 1 | 2 | | 2003 | 1 | 0 | 1 | | 2004 | 2 | 1 | 3 | | 2005 | 0 | 1 | 1 | | 2006 | 1 | 0 | 1 | | 2007 | 1 | 0 | 1 | | 2008 | 2 | 0 | 2 | | 2009 | 1 | 1 | 2 | | 2010 | 2 | 1 | 3 | | 2011 | 2 | 0 | 2 | | 2012 | 3 | 3 | 6 | | 2013 | 2 | 1 | 3 | | 2014 | 3 | 1 | 4 | | 2015 | 2 | 2 | 4 | | 2016 | 3 | 2 | 5 | | 2017 | 1 | 1 | 2 | | 2018 | 8 | 3 | 11 | | 2019 | 14 | 5 | 19 | | 2020 | 10 | 4 | 14 | | 2021 | 13 | 7 | 20 | | 2022 | 3 | 13 | 16 | | 2023 | 1 | 11 | 12 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Lamble AJ, Moskop A, Pulsipher MA, Maude SL, Summers C, Annesley C, Baruchel A, Gore L, Amrolia P, Shah N. INSPIRED Symposium Part 2: Prevention and Management of Relapse Following Chimeric Antigen Receptor T Cell Therapy for B Cell Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2023 Nov; 29(11):674-684.
-
Thompson B, Strange A, Amato CM, Hester-McCullough J, Sarnaik AA, Weber JS, Woods DM. CD4 Phenotypes Are Associated with Reduced Expansion of Tumor-Infiltrating Lymphocytes in Melanoma Patients Treated with Adoptive Cell Therapy. J Immunol. 2023 09 01; 211(5):735-742.
-
Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar MK, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson S, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas Bisneto JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade MJ, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline J. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv. 2023 08 22; 7(16):4528-4538.
-
Locatelli F, Shah B, Thomas T, Velasco K, Adedokun B, Aldoss I, Gore L, Hoelzer D, Bassan R, Park JH, Boissel N, Kantarjian H. Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review. Leuk Lymphoma. 2023 10; 64(10):1615-1633.
-
Shouse G, Kaempf A, Gordon MJ, Artz A, Yashar D, Sigmund AM, Smilnak G, Bair SM, Mian A, Fitzgerald LA, Bajwa A, Jaglowski S, Bailey N, Shadman M, Patel K, Stephens DM, Kamdar M, Hill BT, Gauthier J, Karmali R, Nastoupil LJ, Kittai AS, Danilov AV. A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma. Blood Adv. 2023 Jul 25; 7(14):3516-3529.
-
Holland EM, Yates B, Steinberg SM, Yuan CM, Wang HW, Annesley C, Shalabi H, Stroncek D, Fry TJ, Krueger J, Jacoby E, Hsieh E, Bhojwani D, Gardner RA, Maude SL, Shah NN. Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure. Transplant Cell Ther. 2023 09; 29(9):574.e1-574.e10.
-
Jess J, Yates B, Dulau-Florea A, Parker K, Inglefield J, Lichtenstein D, Schischlik F, Ongkeko M, Wang Y, Shahani S, Cullinane A, Smith H, Kane E, Little L, Chen D, Fry TJ, Shalabi H, Wang HW, Satpathy A, Lozier J, Shah NN. CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity. J Immunother Cancer. 2023 Jun; 11(6).
-
Crotty EE, Wilson AL, Davidson T, Tahiri S, Gust J, Griesinger AM, Venkataraman S, Park JR, Mueller S, Rood BR, Hwang EI, Wang LD, Vitanza NA. Cellular Therapy for Children with Central Nervous System Tumors: Mining and Mapping the Correlative Data. Curr Oncol Rep. 2023 Aug; 25(8):847-855.
-
Nixdorf D, Sponheimer M, Berghammer D, Engert F, Bader U, Philipp N, Kazerani M, Straub T, Rohrbacher L, Wange L, Dapa S, Atar D, Seitz CM, Brandstetter K, Linder A, von Bergwelt M, Leonhardt H, Mittelstaet J, Kaiser A, B?cklein V, Subklewe M. Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML. Leukemia. 2023 06; 37(6):1298-1310.
-
Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Crotta A, Montheard S, Previtali A, Ogasawara K, Kamdar M. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023 04 06; 141(14):1675-1684.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|